NASDAQ NMS - GLOBAL MARKET · GRCE
+2.80% · +$0.0600 · Vol 75.9K
Market closed · last close 4:00 PM ET · price as of 16:00:00 ET
Grace Therapeutics, Inc

Grace Therapeutics, Inc

Pharmaceuticals
$2.20
Card
Relationship Map

Veridion Score

BETAHIGH CONF · 6/6 factorsMethodology
GRCE
Grace Therapeutics, Inc
Fri Aug 21 · last completed session · Markets closed · resumes Mon 9:30 ET
STRONG

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

80/ 100
Veridion Score
STRONG · HIGH confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: HIGH · 6/6 factors with data · Fri Aug 21 · last completed session · Markets closed · resumes Mon 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is GRCE moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading GRCE catalysts
About Grace Therapeutics, Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2011
Employees
5
Country
US

Grace Therapeutics Inc is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its development pipeline consists of the following product candidates: GTx-104, a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage (aSAH); GTx-102, targeted for the treatment of ataxia-telangiectasia (A-T) in a pediatric population; and GTx-101, a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia (PHN), which can be persistent and often causes debilitating pain following infection by the shingles virus. The company has one reportable operating segment: the development and commercialization of pharmaceutical applications of its patents and licensed rights.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$2.15
Day high
$2.23
Day low
$2.15
Previous close
$2.14
52W high
$5.13
-57.12% from high
52W low
$2.07
4% of range
Market cap
$46.3M
EPS
$-1.3200
Beta
1.29
Shares out
21M
Volume
75.9K
0.36× rel vol
Avg volume
213.5K
VWAP
$2.20
Price history computed in-house
1W
+1.85%
1M
-5.58%
3M
-6.78%
1Y
-32.31%
YTD
-36.42%
SMA 50 $2.28 · below
SMA 200 $3.12 · below
52W position 4%

GRCE overview

Veridion Score
80
Registered · 2026-08-21
6 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around GRCE.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading GRCE Form 4 filings
Public disclosures

Congress activity in GRCE

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for GRCE in the cached public ledger.

Federal contracts

GRCE contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for GRCE in this window.
Lobbying spend

GRCE lobbying filings, year to date.

Registered lobbying filings matched to Grace Therapeutics, Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for GRCE in this window.
Loading news for GRCE
Analyst ratings
Sovereign unlock shows live analyst consensus for GRCE.
Options
Sovereign unlock shows live options positioning for GRCE.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.